, /PRNewswire/ -- Wren Laboratories, a leader in novel in-vitro diagnostic (IVD) technologies, announced today significant enhancements to its executive leadership team. These changes aim to strengthen Wren's commercial operations and expand its market presence as part of the company's ongoing strategy to foster growth and innovation in diagnostic solutions. While extending its current standard-of-care testing, Wren Laboratories now expands services to Biopharma with AI/ML liquid biopsy genomic assays for translational research and companion diagnostics (CDx) development.
Since 2014, Wren has been enhancing precision medicine by harnessing data and Al for healthcare excellence to provide physicians with valuable insights in cancer diagnostics and disease monitoring. Leveraging their CLIA-certified, CAP-accredited, and -licensed clinical laboratory, Wren is set to deliver unparalleled precision and reliability in diagnostic innovation. now leads Wren Laboratories as Chief Executive Officer and Chief Scientific Officer, bringing an exceptional blend of biotech leadership and strategic growth expertise.
Renowned for his visionary approach, Dr. Halim is poised to propel Wren into a new era of innovation and operational excellence. Under his guidance, Wren will not only amplify its diagnostic capabilities but also achieve unprecedented efficiency in its operations.
Dr. Halim stands out as one of only four lab professionals in the who holds triple-board certifications in Molecular .
